Psyence Biomedical Ltd. (PBM)
0.61
-0.06 (-8.96%)
At close: Mar 21, 2025, 3:56 PM
-8.96% (1D)
| Bid | 0.58 |
| Market Cap | 2.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -347.63M |
| EPS (ttm) | -76.91 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.72 |
| Volume | 37,342 |
| Avg. Volume (20D) | 431,115 |
| Open | 0.65 |
| Previous Close | 0.67 |
| Day's Range | 0.61 - 0.65 |
| 52-Week Range | 0.61 - 108.00 |
| Beta | -0.45 |
About PBM
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including asso...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 10, 2021
Employees 10
Stock Exchange NASDAQ
Ticker Symbol PBM
Website https://www.psyencebiomed.com
3 months ago
-25.16%
Psyence Biomedical shares are trading lower after ...
Unlock content with
Pro Subscription
3 months ago
+60.78%
Psyence Biomedical shares are trading higher. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.
